- Business
- Henan Lingrui Pharmaceutical Co., Ltd., founded in June 1992 and headquartered in Henan, China, is a national high-tech pharmaceutical enterprise specializing in the research, development, production, and sales of pharmaceuticals and medical devices. The company manufactures over 100 products across more than 10 dosage forms including adhesive plasters, tablets, capsules, granules, ointments, tinctures, and sprays, covering therapeutic areas such as orthopedics, cardiovascular and cerebrovascular diseases, pulmonology, dermatology, endocrinology, and anesthesiology. Key products include Tongluoqutong Plasters, Peiyuantongnao Capsules, Danlutongdu Tablets, Shenqi Hypoglycemic Capsules, and salmon calcitonin nasal spray. Henan Lingrui also operates through several subsidiaries across Beijing, Changzhou, Zhengzhou, and Xinyang, primarily serving the Chinese domestic market with a focus on markets in Henan Province and Beijing.
The company maintains GMP certification for all its dosage forms, products, and manufacturing workshops, ensuring compliance with national and international quality standards. Recently, Henan Lingrui Pharmaceutical has been emphasizing innovative pharmaceutical commercialization and export growth, reversing previous declines in overseas authorization trade, signaling a strategic expansion toward international markets. In the last 1-2 years, Henan Lingrui has been actively developing new product offerings and furthering R&D capabilities, while maintaining its strong presence in traditional Chinese medicine treatments for orthopedic and cardiovascular diseases. It has strategically diversified into health care products and maintained significant innovation with products that possess exclusive intellectual property rights. The firm continues to solidify its status as a leading enterprise in China's pharmaceutical sector, ranking among the top traditional Chinese medicine enterprises with multiple awards at municipal, provincial, and national levels. Its latest financial trends indicate a positive short-term market outlook supported by solid fundamentals and increasing liquidity.
Henan Lingrui's business segments include pharmaceutical and health care, focusing on plasters, oral medicines, and ointments, with ancillary businesses in hospitality and catering. The company is publicly listed on the Shanghai Stock Exchange under ticker 600285.SS and reported nearly 3.7 billion CNY in revenue (TTM). Its strategic goals include leveraging unique proprietary formulations and expanding its footprint in both domestic and selected international markets.
This comprehensive approach across R&D, manufacturing, and sales, combined with recent operational expansions and export growth, positions Henan Lingrui Pharmaceutical as a significant player in the pharmaceutical industry in China and increasingly in global markets.